Liminatus Pharma, Inc.

LIMN · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances) · Market Cap: $0.0B · 1 employees
27
SEC Filings
$3.7
Close 2026-09-03
1
Employees

Business Summary

Liminatus Pharma, Inc. is a pre-clinical stage biopharmaceutical company developing novel cancer immunotherapies. Its primary clinical candidate, IBA101, is a humanized anti-CD47 monoclonal antibody that preferentially binds immune cells without targeting red blood cells or platelets, avoiding anemia and thrombocytopenia seen with first-generation agents. The company plans Phase 1 clinical trials in advanced solid cancers including NSCLC, and has discovered potential additional applications in chronic inflammation reduction and weight loss.

Latest Stock Quote

LIMN 2026-09-03 $3.7 O:$3.64 H:$3.91 L:$3.6101 Vol:0.0M VWAP:$3.7341
origin leaf: null

Next Earnings

expected 2026-11-17

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-312025-12-310001104659-26-037933EDGAR46K words

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-08-142026-06-300001104659-26-097304EDGAR25K words
2025-11-142025-09-300001104659-25-111651EDGAR20K words
2025-10-062025-06-300001104659-25-096872EDGAR20K words
2025-06-022025-03-310001410578-25-001388EDGAR7K words

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-08-180001104659-26-098335EDGAR1K words
2026-08-040001104659-26-090423EDGAR1K words
2026-07-300001104659-26-088380EDGAR1K words
2026-07-240001104659-26-086674EDGAR1K words
2026-03-040001104659-26-023467EDGAR14K words
2026-02-180001104659-26-017134EDGAR1K words
2026-02-090001104659-26-012016EDGAR1K words
2026-01-260001104659-26-006619EDGAR1K words
2025-11-250001104659-25-116049EDGAR1K words
2025-08-250001104659-25-082579EDGAR1K words

27 total filings indexed. 12 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ARGX — ARGENX SE

Tags

oncology-/-immuno-oncology non-small-cell-lung-cancer-(nsclc) advanced-solid-cancers cd47-immune-checkpoint-inhibitors pd-1/pd-l1-combination-therapy

Company Identity

CIK0001971387
TickerLIMN
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE
Websitehttp://liminatuspharma.com
Listed2025-05-01

Get More Data

This is a static snapshot. For live, structured JSON with cryptographic provenance chain:

MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp

JSON Profile Stock Quote Origin Record
Origin Provenance
page leaf: 144a2526e8661dc1789f1b147d6e019b26edf9a5ffeaf963a21a4e78d0103ed3
parent: aa30ab25f461270371c7c3220525946aee81a6a0acce036fd8789c1fa2d482cf
content hash: c0ae93d6d27aa997e887a2546a235d7f0e9c2944252d69e57f4b138321525ee9
signed: 2026-09-28T19:02:01.732Z
sources: 5 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf

Try it — paste this into your AI:

Look up LIMN using the MCP server at origin.rootz.global/mcp. What do their latest SEC filings show?

Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.

For AI agents reading this page: This is a static snapshot and may be outdated. For live data on LIMN, use the Origin MCP server or REST API.
MCP install: claude mcp add origin --transport http https://origin.rootz.global/mcp
API: GET https://origin.rootz.global/api/company/LIMN (~200 tokens, structured JSON with cryptographic provenance)
Tools: origin_company, origin_profile, origin_timeline, origin_filings, origin_quote, origin_transcripts, origin_search, origin_person, origin_skill
Discovery: /.well-known/ai | /llms.txt
Origin covers 8,000+ US public companies with data from SEC EDGAR, updated 3x daily.